公开(公告)号：US11642339B2

公开(公告)日：2023-05-09

申请号：US16048933

申请日：2018-07-30

申请人： THERAVANCE BIOPHARMA R&D IP, LLC ,  ALFASIGMA S.P.A.

发明人： Christopher Noel Barnes ,  Giuseppe Claudio Viscomi ,  Cecilia Renzulli ,  Maria Grimaldi

IPC分类号： A61K31/4704 ,  A61P1/08 ,  A61P1/06 ,  A61P1/04 ,  A61K9/48 ,  A61K31/55

CPC分类号： A61K31/4704 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/55 ,  A61P1/04 ,  A61P1/06 ,  A61P1/08

摘要： The present invention relates to methods and pharmaceutical compositions for treatment of all symptoms of gastroparesis in a human patient, the method comprising administering to the human patient between about 0.5 mg/day to about 30 mg/day, about 0.5 mg/day to about 15 mg/day, about 0.5 mg/day to about 5 mg/day, or about 5 mg/day, of velusetrag or a pharmaceutically-acceptable salt thereof.

公开(公告)号：US11484531B2

公开(公告)日：2022-11-01

申请号：US16555216

申请日：2019-08-29

申请人： THERAVANCE BIOPHARMA R&D IP, LLC

发明人： Christopher Noel Barnes ,  Glenn D. Crater ,  Edmund J. Moran ,  Srikanth Pendyala

IPC分类号： A61K31/444 ,  A61K9/00 ,  A61P11/06 ,  A61K31/135 ,  A61K45/06

摘要： Methods for treating chronic obstructive pulmonary disease (COPD) in a patient are disclosed. In the methods, a patient having COPD is selected for treatment based on the patient's peak inspiratory flow rate (PIFR) and percent predicted force expiratory volume in one second (FEV1); and a bronchodilator is administered to the selected patient using a nebulizer. Administration of a bronchodilator to patients having low PIFR and a percent predicted FEV1 less than 50 percent using a nebulizer as the inhalation delivery device provides significantly greater improvements in trough FEV1 and trough forced vital capacity (FVC) compared to administration of a bronchodilator to such patients using a dry powder inhaler.

公开(公告)号：US12048692B2

公开(公告)日：2024-07-30

申请号：US18137919

申请日：2023-04-21

申请人： THERAVANCE BIOPHARMA R&D IP, LLC

发明人： Christopher Noel Barnes ,  Glenn D. Crater ,  Edmund J. Moran ,  Srikanth Pendyala

IPC分类号： A61K31/444 ,  A61K9/00 ,  A61K31/135 ,  A61P11/06 ,  A61K45/06

CPC分类号： A61K31/444 ,  A61K9/0078 ,  A61K31/135 ,  A61P11/06 ,  A61K45/06

摘要： Methods for treating chronic obstructive pulmonary disease (COPD) in a patient are disclosed. In the methods, a patient having COPD is selected for treatment based on the patient's peak inspiratory flow rate (PIFR) and percent predicted force expiratory volume in one second (FEV1); and a bronchodilator is administered to the selected patient using a nebulizer. Administration of a bronchodilator to patients having low PIFR and a percent predicted FEV1 less than 50 percent using a nebulizer as the inhalation delivery device provides significantly greater improvements in trough FEV1 and trough forced vital capacity (FVC) compared to administration of a bronchodilator to such patients using a dry powder inhaler.